Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

About the trial

Sponsor

Eidos Therapeutics, a BridgeBio company

Tested

Acoramidis (drug), Placebo oral tablet (drug)

Dates

Started 2025-05-12; completion 2032-12

Results posted

Not yet

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can…

From ClinicalTrials.gov, last updated 2026-08-04. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eidos Therapeutics, Inc. reported $1.1M in research payments for this study in 2025 (178 payments).

Products named: Attruby

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.